Exchange: NASDAQ·Updated 02:41 PM EST
BCAX logo

BCAX Bicara Therapeutics

$9.38
$0.22
(2.29%)
Today
Reported EarningsNov 9
Mkt Cap$637.32M
Vol447,389.00

About BCAX

Bicara Therapeutics, Inc. is a clinical-stage biotechnology company and develops biologics engineered to combine the precision of well validated, tumor-targeting antibodies with the power of tumor microenvironment modulators. The company’s bi-functional antibodies are designed to deliver an immunomodulatory payload directly to the tumor microenvironment to ramp up immune cell activity, offering the potential for synergistic therapeutic impact at the site of the tumor. Its products include BCA101, a first-in-class EGFR/TGF-ß-trap bifunctional antibody in clinical development for multiple tumor types. The company was founded on December 12, 2018 and is headquartered in Boston, MA.
45

Neutral Sentiment

How do you feel about BCAX?

kdretirein10
$BCAX this stock will only move in the direction of the overall consensus of the majority of shareholders and what they believe this stock is worth now and at some future date. Don't believe that one competitor's good news need destroy everything this company has accomplished. They have enough cash, $496 million to carry this company through 2029 with out any diluting with warrants.
6
Florestan
$BCAX as expected, GMAB readout flushing this hard. On the bright side, we still have a mechanistically differentiated drug, nothing to do with wait until the pivotal data.
1
2
Jloveissoreal
$BCAX An analyst report summary for Bicara Therapeutics Inc. (NASDAQ: BCAX) reflects a consensus Buy rating based on current wall street coverage and price target data. Analyst Ratings & Consensus • Consensus Rating: Buy (12 Buys, 1 Hold, 0 Sells out of 13 active ratings) • Average Price Target: $35.09 • Price Target Range: • High: $45.00 • Median: $35.00 • Low: $20.00
4
kdretirein10
$BCAX today we got a new 52 week low of $8.90 for no real apparent reason. For all you chicken littles out there that keep selling, you need to go back across the road and get your brain cells evaluated. This stock is being beaten up for nothing. It will go back up and all the analysts covering this stock agree. This business has over $460 million in cash to support this business into 2029. I would start buying shares now that the damage was done just because this company is worth so much more than the current share price.
4
kdretirein10
$BCAX BTIG reiterates buy with a $39 price target. This was posted on Schwab Think or Swim at 10:46 ET
4
bsprelude
$BCAX Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Bicara Therapeutics Inc. today and set a price target of $34.00. Tazeen Ahmad has given his Buy rating due to a combination of factors, including management’s strong confidence in ficera ahead of the mid-2027 interim phase 3 readout in first-line HPV-negative head and neck cancer. She views ficera’s differentiated efficacy, particularly its higher complete response rate, deep tumor reductions, and durable progression-free survival, as positioning Bicara well versus competing therapies. Many analysts are coming to the defense of BCAX with reiteration of strong buy! mid 30’s PT!!!
3
LF5
$BCAX This is overdone which is very typical of a bio. Hoping more buyers realize it and start buying. Upside looks pretty good from here imo.
3
permabull869
$BCAX thinking it closes at least over 11, if not 12. But rest of the recovery will take time.
3
permabull869
$BCAX just seems like a big overreaction with bounce in next week or so. Lots of other eyes on this, competition information is not new.
3
Icemanja
$BCAX November 10, 2026, Stifel maintained its Buy rating on Bicara Therapeutics Inc. while lowering its price target from $45.00 to $43.00
1
bsprelude
$BCAX Analysts from Wedbush, BofA, Morgan Stanley, BTIG, and BMO Capital all reiterated buy status for BCAX… an uncalled for drop after Genmab reported good results. AVG Price Target is mid $30’s
1
ForkMAN
$BCAX Gotta be good for at least a bounce here. This moved because if another companies data. Too early to jump ship.
1
jskstocks
$BCAX Genmab was not specific enough about their results to compare apples to apples, but it looks like Ficera is at least as good or better than petosemtamab. For Genmab, their objective response rate (ORR) versus pembrolizumab was [OS: HR 0.50 (95% CI, 0.37, 0.67); p<0.0001. For $BCAX, their objective response rate (ORR) versus pembrolizumab was OS: HR 0.35 (95% CI, 0.13, 1.10). Given Genmab was a well powered P3 trial and Bicara's trial was a smaller P2 with a lower statistical confidence it is fair to assume Genmab has the commercial lead and Bicara still has to prove in P3 trial, the investment thesis is that even with superiority for Ficera they have significant competition. The sell-off made sense, but was probably overdone and the Bicara trial is really only 6-9 months behind Genmab.
1
TheTinyDevil
$BCAX Hi, do you have any link/article about what's up here - or could provide a quick & dirty summary? Thanks.
1
shoc24
$BCAX reported earnings before the open today. GAAP EPS missed estimates: -$1.04 vs. -$0.82 expected, according to Stock Meadow.
StocktwitsEarnings
$BCAX Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$1.04 down -55.22% YoY • Bicara expects existing cash, cash equivalents and marketable securities to fund operations into the first half of 2029, based on current operating and development plans.
WarrenDouglasTrader
$BCAX So, only catalyst in binary all or nothing p3 read out mid 2027. No way for stock to rise until then?
cjmeyer
$BCAX Typical Wall Street Scam.Downgrade it and have institutions dump before the downgrade gets reported.Bunch of crooks.
Phonic
$BCAX On my watch list. Only issue is that there is still time to make some meaningful catalyst - I could be wrong and would welcome correction. But it could be another 9 months for something meaningful. That said.. the price is heavily discounted. Today is trading normally compared to yesterday and so stayed away. Ill still watch... if it gets close to 9 again I may dip a toe in.
Robcat
$BCAX Start a position at 9. This should be punished so much like OCUL the other day, just because of the competitor!!!

Advertisement|Remove ads.